CITIUS PHARMACEUTICALS INC (CTXR) Stock Price & Overview
NASDAQ:CTXR • US17322U3068
The current stock price of CTXR is 0.839 USD. Today CTXR is up by 0.47%. In the past month the price increased by 11.17%. In the past year, price decreased by -44.07%.
CTXR Key Statistics
- Market Cap
- 18.777M
- P/E
- N/A
- Fwd P/E
- 0.29
- EPS (TTM)
- -4.09
- Dividend Yield
- N/A
CTXR Stock Performance
CTXR Stock Chart
CTXR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CTXR. When comparing the yearly performance of all stocks, CTXR is a bad performer in the overall market: 90.88% of all stocks are doing better.
CTXR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTXR. CTXR may be in some trouble as it scores bad on both profitability and health.
CTXR Earnings
CTXR Forecast & Estimates
8 analysts have analysed CTXR and the average price target is 5.1 USD. This implies a price increase of 507.87% is expected in the next year compared to the current price of 0.839.
For the next year, analysts expect an EPS growth of 141.4% and a revenue growth 731.6% for CTXR
CTXR Groups
Sector & Classification
CTXR Financial Highlights
Over the last trailing twelve months CTXR reported a non-GAAP Earnings per Share(EPS) of -4.09. The EPS increased by 29.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.56% | ||
| ROE | -44.88% | ||
| Debt/Equity | 0.01 |
CTXR Ownership
CTXR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.85 | 934.238B | ||
| JNJ | JOHNSON & JOHNSON | 20.83 | 579.34B | ||
| MRK | MERCK & CO. INC. | 22.63 | 286.278B | ||
| PFE | PFIZER INC | 8.98 | 153.814B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.57 | 122.779B | ||
| ZTS | ZOETIS INC | 17.29 | 51.259B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.87 | 26.195B | ||
| VTRS | VIATRIS INC | 5.67 | 16.304B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.76 | 11.614B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.303B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.501B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.547B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.59 | 4.166B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTXR
Company Profile
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Company Info
CITIUS PHARMACEUTICALS INC
11 Commerce Dr Fl 1
Cranford NEW JERSEY 07016 US
CEO: Myron Holubiak
Employees: 23
Phone: 19089676677
CITIUS PHARMACEUTICALS INC / CTXR FAQ
What does CTXR do?
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
What is the stock price of CITIUS PHARMACEUTICALS INC today?
The current stock price of CTXR is 0.839 USD. The price increased by 0.47% in the last trading session.
Does CITIUS PHARMACEUTICALS INC pay dividends?
CTXR does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTXR stock?
CTXR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is CTXR stock listed?
CTXR stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of CITIUS PHARMACEUTICALS INC (CTXR)?
CITIUS PHARMACEUTICALS INC (CTXR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.09).
Can you provide the market cap for CITIUS PHARMACEUTICALS INC?
CITIUS PHARMACEUTICALS INC (CTXR) has a market capitalization of 18.78M USD. This makes CTXR a Nano Cap stock.